Daiichi Sankyo and Waiv partner for ADC biomarkers

Pharmaceutical Technology

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

pharminent May 7, 2026 (Last updated: May 7, 2026)

Pharmaceutical Technology

Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.

Related Stories